112 related articles for article (PubMed ID: 21317397)
1. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.
Lohse S; Derer S; Beyer T; Klausz K; Peipp M; Leusen JH; van de Winkel JG; Dechant M; Valerius T
J Immunol; 2011 Mar; 186(6):3770-8. PubMed ID: 21317397
[TBL] [Abstract][Full Text] [Related]
2. Serum-free production and purification of chimeric IgA antibodies.
Beyer T; Lohse S; Berger S; Peipp M; Valerius T; Dechant M
J Immunol Methods; 2009 Jul; 346(1-2):26-37. PubMed ID: 19427867
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens.
Dhein J; Daniel PT; Trauth BC; Oehm A; Möller P; Krammer PH
J Immunol; 1992 Nov; 149(10):3166-73. PubMed ID: 1431095
[TBL] [Abstract][Full Text] [Related]
4. Epithelial transcytosis of monomeric IgA and IgG cross-linked through antigen to polymeric IgA. A role for monomeric antibodies in the mucosal immune system.
Kaetzel CS; Robinson JK; Lamm ME
J Immunol; 1994 Jan; 152(1):72-6. PubMed ID: 8254208
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
6. Shiga toxin-induced apoptosis is more efficiently inhibited by dimeric recombinant hybrid-IgG/IgA immunoglobulins than by the parental IgG monoclonal antibodies.
Kurohane K; Nagano K; Nakanishi K; Iwata K; Miyake M; Imai Y
Virulence; 2014; 5(8):819-24. PubMed ID: 25469594
[TBL] [Abstract][Full Text] [Related]
7. Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies.
Lohse S; Peipp M; Beyer T; Valerius T; Dechant M
Arch Immunol Ther Exp (Warsz); 2010 Aug; 58(4):303-12. PubMed ID: 20508996
[TBL] [Abstract][Full Text] [Related]
8. Secretory component delays the conversion of secretory IgA into antigen-binding competent F(ab')2: a possible implication for mucosal defense.
Crottet P; Corthésy B
J Immunol; 1998 Nov; 161(10):5445-53. PubMed ID: 9820520
[TBL] [Abstract][Full Text] [Related]
9. Stable expression and characterization of monomeric and dimeric recombinant hybrid-IgG/IgA immunoglobulins specific for Shiga toxin.
Iwata K; Kurohane K; Nakanishi K; Miyake M; Imai Y
Biol Pharm Bull; 2014; 37(9):1510-5. PubMed ID: 24989136
[TBL] [Abstract][Full Text] [Related]
10. Mechanism for enhanced external transfer of dimeric IgA over pentameric IgM: studies of diffusion, binding to the human polymeric Ig receptor, and epithelial transcytosis.
Natvig IB; Johansen FE; Nordeng TW; Haraldsen G; Brandtzaeg P
J Immunol; 1997 Nov; 159(9):4330-40. PubMed ID: 9379029
[TBL] [Abstract][Full Text] [Related]
11. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor.
Dechant M; Beyer T; Schneider-Merck T; Weisner W; Peipp M; van de Winkel JG; Valerius T
J Immunol; 2007 Sep; 179(5):2936-43. PubMed ID: 17709508
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.
Lohse S; Brunke C; Derer S; Peipp M; Boross P; Kellner C; Beyer T; Dechant M; van der Winkel JG; Leusen JH; Valerius T
J Biol Chem; 2012 Jul; 287(30):25139-50. PubMed ID: 22679018
[TBL] [Abstract][Full Text] [Related]
13. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
[TBL] [Abstract][Full Text] [Related]
15. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
[TBL] [Abstract][Full Text] [Related]
16. Simplifying the synthesis of SIgA: combination of dIgA and rhSC using affinity chromatography.
Moldt B; Saye-Francisco K; Schultz N; Burton DR; Hessell AJ
Methods; 2014 Jan; 65(1):127-32. PubMed ID: 23811333
[TBL] [Abstract][Full Text] [Related]
17. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
18. Mouse IgA Fc receptor on CD3+ T cells. Molecular forms of IgA that bind to a 38-kDa Fc alpha R protein and development of an anti-Fc alpha R antisera.
Aicher WK; McGhee ML; McGhee JR; Eldridge JH; Beagley KW; Meyer TF; Kiyono H
J Immunol; 1990 Sep; 145(6):1745-53. PubMed ID: 2144006
[TBL] [Abstract][Full Text] [Related]
19. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous expression of a low affinity Fc receptor for IgA (Fc alpha R) on human B cell lines.
Millet I; Briere F; Vincent C; Rousset F; Andreoni C; De Vries JE; Revillard JP
Clin Exp Immunol; 1989 May; 76(2):268-73. PubMed ID: 2788048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
